BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 31078941)

  • 21. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
    Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
    Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.
    Peng H; Tang LL; Chen BB; Chen L; Li WF; Mao YP; Liu X; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    Oral Oncol; 2018 Apr; 79():40-46. PubMed ID: 29598949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
    Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
    Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
    Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
    Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
    Zhao L; Xu M; Jiang W; Pan H; Zang J; Luo S; Wang J; Zhou Y; Shi M
    Oncotarget; 2017 Jan; 8(4):6763-6774. PubMed ID: 28036270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
    Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
    Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.
    Peng H; Chen L; Zhang Y; Li WF; Mao YP; Liu X; Zhang F; Guo R; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    Sci Rep; 2016 Apr; 6():24835. PubMed ID: 27099096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma].
    Liu KQ; Jin F; Jiang H; Wu WL; Li YY; Long JH; Luo XL; Gong XY; Chen XX; Liu LN; Gan JY; Zhou JJ
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):133-138. PubMed ID: 32135648
    [No Abstract]   [Full Text] [Related]  

  • 38. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
    Fountzilas G; Ciuleanu E; Bobos M; Kalogera-Fountzila A; Eleftheraki AG; Karayannopoulou G; Zaramboukas T; Nikolaou A; Markou K; Resiga L; Dionysopoulos D; Samantas E; Athanassiou H; Misailidou D; Skarlos D; Ciuleanu T
    Ann Oncol; 2012 Feb; 23(2):427-35. PubMed ID: 21525406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
    Zong J; Xu H; Chen B; Guo Q; Xu Y; Chen C; Weng Y; Zheng W; Pan J; Lin S
    Radiat Oncol; 2019 Oct; 14(1):182. PubMed ID: 31640719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.